Biomarin Pharmaceutical (BMRN) Current Deferred Tax Assets (2010 - 2015)

Biomarin Pharmaceutical has disclosed Current Deferred Tax Assets across 6 years of filings, most recently posting $30.9 million for Q3 2015.

• Quarterly Current Deferred Tax Assets rose 5.94% year-over-year to $30.9 million in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $30.9 million (up 5.94% YoY) and the FY2014 annual result came in at $31.2 million, up 2.09% from the prior year.
• Current Deferred Tax Assets retreated to $30.9 million in Q3 2015, from $31.2 million in the prior quarter.
• Over five years, Current Deferred Tax Assets peaked at $32.4 million in Q4 2012 and troughed at $16.7 million in Q2 2011.
• A 5-year average of $27.2 million and a median of $30.0 million in 2013 frame the typical range for Current Deferred Tax Assets.
• Annual changes were most pronounced in 2012 — Current Deferred Tax Assets soared 53.24% — and 2014, when it fell 9.58%.
• Tracing BMRN's Current Deferred Tax Assets over 5 years: stood at $21.1 million in 2011, then surged by 53.24% to $32.4 million in 2012, then retreated by 5.55% to $30.6 million in 2013, then advanced by 2.09% to $31.2 million in 2014, then fell by 1.03% to $30.9 million in 2015.
• Business Quant data shows BMRN's Current Deferred Tax Assets at $30.9 million in Q3 2015, $31.2 million in Q2 2015, and $31.2 million in Q1 2015.